Novartis Remibrutinib Receives Positive European Opinion, Meets Endpoint in CIndU Trial
Mar 08, 2026
Novartis announced positive European regulatory opinion for remibrutinib in chronic spontaneous urticaria and reported the drug met its primary endpoint in a Phase 3 trial for chronic inducible urticaria.